Study S000940

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02477865
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: UNKNOWN
Enrollment: 406
Start: 2014-03-23
Primary completion: 2016-05-15
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [Baseling to 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.